Tissue | Expression Dynamics | Abbreviation |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000838016 | Endometrium | AEH | RNA splicing | 111/2100 | 434/18723 | 2.42e-17 | 1.12e-14 | 111 |
GO:000645710 | Endometrium | AEH | protein folding | 61/2100 | 212/18723 | 1.86e-12 | 3.48e-10 | 61 |
GO:00004133 | Endometrium | AEH | protein peptidyl-prolyl isomerization | 13/2100 | 42/18723 | 4.74e-04 | 4.91e-03 | 13 |
GO:00182086 | Endometrium | AEH | peptidyl-proline modification | 16/2100 | 58/18723 | 4.75e-04 | 4.91e-03 | 16 |
GO:000838017 | Endometrium | EEC | RNA splicing | 111/2168 | 434/18723 | 2.45e-16 | 1.13e-13 | 111 |
GO:000645715 | Endometrium | EEC | protein folding | 63/2168 | 212/18723 | 6.82e-13 | 1.40e-10 | 63 |
GO:000041311 | Endometrium | EEC | protein peptidyl-prolyl isomerization | 14/2168 | 42/18723 | 1.69e-04 | 2.10e-03 | 14 |
GO:001820813 | Endometrium | EEC | peptidyl-proline modification | 17/2168 | 58/18723 | 2.11e-04 | 2.54e-03 | 17 |
GO:000838026 | Esophagus | HGIN | RNA splicing | 160/2587 | 434/18723 | 3.74e-34 | 1.12e-30 | 160 |
GO:000645720 | Esophagus | HGIN | protein folding | 75/2587 | 212/18723 | 1.61e-15 | 3.86e-13 | 75 |
GO:00182089 | Esophagus | HGIN | peptidyl-proline modification | 17/2587 | 58/18723 | 1.64e-03 | 1.82e-02 | 17 |
GO:00004135 | Esophagus | HGIN | protein peptidyl-prolyl isomerization | 13/2587 | 42/18723 | 3.32e-03 | 3.12e-02 | 13 |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
GO:00083807 | Liver | NAFLD | RNA splicing | 70/1882 | 434/18723 | 4.62e-05 | 1.10e-03 | 70 |
GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
GO:00182084 | Liver | Cirrhotic | peptidyl-proline modification | 26/4634 | 58/18723 | 6.65e-04 | 5.04e-03 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPIG | deletion | Frame_Shift_Del | novel | c.643delG | p.Asp215IlefsTer72 | p.D215Ifs*72 | Q13427 | protein_coding | | | TCGA-60-2715-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | PD |
PPIG | SNV | Missense_Mutation | | c.986C>A | p.Ser329Tyr | p.S329Y | Q13427 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CN-A63V-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PPIG | SNV | Missense_Mutation | novel | c.1841N>A | p.Gly614Glu | p.G614E | Q13427 | protein_coding | tolerated_low_confidence(0.76) | benign(0) | TCGA-CQ-5326-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PPIG | SNV | Missense_Mutation | novel | c.1950N>C | p.Lys650Asn | p.K650N | Q13427 | protein_coding | deleterious_low_confidence(0.01) | benign(0.083) | TCGA-CQ-5326-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PPIG | SNV | Missense_Mutation | novel | c.2100N>C | p.Glu700Asp | p.E700D | Q13427 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.584) | TCGA-D6-8568-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PPIG | SNV | Missense_Mutation | novel | c.2221N>A | p.Asp741Asn | p.D741N | Q13427 | protein_coding | tolerated_low_confidence(0.26) | benign(0.021) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
PPIG | SNV | Missense_Mutation | | c.896N>A | p.Arg299Lys | p.R299K | Q13427 | protein_coding | tolerated(0.67) | benign(0) | TCGA-B7-5818-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PPIG | SNV | Missense_Mutation | | c.1363A>G | p.Arg455Gly | p.R455G | Q13427 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.749) | TCGA-BR-8372-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR |
PPIG | SNV | Missense_Mutation | | c.2072N>G | p.Lys691Arg | p.K691R | Q13427 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-BR-8486-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPIG | SNV | Missense_Mutation | | c.830T>A | p.Ile277Asn | p.I277N | Q13427 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-CG-4442-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |